AstraZeneca accused of cherry-picking vaccine study data
Key Excerpts from Article on Website of ABC News
Posted: April 6th, 2021
AstraZeneca may have included "outdated information" in touting the effectiveness of its COVID-19 vaccine in a U.S. study, federal health officials said Tuesday in an unusual public rift that could further erode confidence in the shot. In an extraordinary rebuke, just hours after AstraZeneca on Monday announced its vaccine worked well in the U.S. study, an independent panel that oversees the study scolded the company for cherry-picking data, according to a senior administration official. The panel wrote to AstraZeneca and U.S. health leaders that it was concerned the company chose to use data that was outdated and potentially misleading instead of the most recent and complete findings. The NIH's Dr. Anthony Fauci told ABC's "Good Morning America" that the incident "really is what you call an unforced error" and that he expects the discrepancy to be straightened out. But that nitty-gritty seldom is seen by the public, something now exposed by the extraordinary microscope being applied to development of the world's COVID-19 vaccines. The vaccine is used widely in Britain, across the European continent and in other countries, but its rollout was troubled by inconsistent study reports about its effectiveness, and then last week a scare about blood clots that had some countries temporarily pausing inoculations. Company executives refused repeated requests from reporters to provide a breakdown of the 141 COVID-19 cases it was using to make the case for the shot's effectiveness.
Note: For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources.